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Abstract  
  
Objectives: To characterise the presentation, clinicopathologic data and outcome of 29 dogs  
with presumed primary renal lymphoma.   
Methods:  Medical  records  of  dogs  with  suspected  primary  renal  lymphoma  from  11  
institutions were assessed retrospectively.   
Results: All dogs were substage b, and lethargy and gastrointestinal signs were common 
presenting complaints, as were azotaemia (n=25; 86%) and erythrocytosis (n=15; 51%) on 
biochemical testing. Ultrasonography typically revealed bilateral renal lesions (n=23; 79%), 
renomegaly (n=22; 76%) and abdominal lymphadenopathy (n=14; 48%). Chemotherapy was 
the only treatment in 23 dogs of which 11 responded, all considered partial response. For all 
dogs the median progression-free survival and median overall survival times were 10 days 
(range: 1 to 126) and 12 days (range: 1 to 212), respectively, and for dogs that responded to 
chemotherapy 41 days (range: 10 to 126) and 47 days (range: 10 to 212), respectively. Clinical 
Significance: Primary renal lymphoma in dogs appears to be associated with a poor 
prognosis and short-lived response to chemotherapy.  
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Introduction  
  
Malignant lymphoma comprises 90% of all canine haematopoietic cancers. Diffuse large B- 
cell lymphoma is most common and for which chemotherapy can result in high response 
rates with median survival times of 7–11 months (Davies et al. 2017). The high grade T-cell 
form may carry a worse prognosis although newer protocols rich in alkylating agents have 
demonstrated  comparable  survival  times  (Brown  et  al.  2018).  However,  extranodal 
lymphoma such as hepatic, hepatosplenic and gastrointestinal are less frequently described 
in the dog; these are mainly T-cell tumours and often associated with poor outcome (Frank 
et al. 2007, Keller et al. 2013).  
  
Renal  involvement  in  canine  multi-centric  lymphoma  has  been  previously  recognised,  
typically  at  an  advanced  tumour  stage  (Breshears  et  al.  2011).  The  prevalence  of  primary  
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renal lymphoma (PRL), in which the neoplasia originates from the kidneys, is unknown in 
dogs. Literature regarding presumed primary renal lymphoma is sparse and only a small 
number (<30 cases) have been reported. Most had bilateral involvement and five were T- 
cell and one was B-cell (Baskin & De Paoli 1977, Batchelor et al. 2006, Breshears et al. 2011, 
Cook  &  Lothrop  1994,  Cotchin  1954,  Durno  et  al.  2011,  Froment  &  Gara-Boivin  2015, 
Hilscher 2004, Klein et al. 1988, Lane & Lobetti 2002, Lascelles et al. 2003, Nelson et al. 
1983, Osborne et al. 1971, Snead 2005, Szatmári et al. 2004, Walter et al. 1987, Zhao et al. 
1993). An association with erythrocytosis, as seen with other canine renal neoplasms, and 
CNS (central nervous system) involvement, was common. Only five cases received 
chemotherapy, of which one was managed for 11 months. One dog with unilateral disease 
underwent nephrectomy but died postoperatively of aspiration pneumonia. Full staging was 
not documented in any dog, but at necropsy four fit the definition of primary renal 
lymphoma and another had concurrent disease in the central nervous system only. Feline 
renal  lymphoma  has  typically  been  described  with  involvement  of  other  anatomical 
locations, although as a primary form in 24% of cats. It is mostly of B-cell origin and 
intermediate to high grade, and up to 40% of affected cases can have the CNS affected. 
Though chemoresponsive, the median survival time is less than 7 months (Mooney et al. 
1987, Gabor et al. 1998, 1999, Taylor et al. 2009). 
 
In humans both Non-Hodgkin lymphoma with renal involvement and primary renal 
lymphoma are uncommon (Stallone et al. 2000, Villa et al. 2011). Flank pain, inappetence, 
weight loss, haematuria, fever and acute renal failure are common as is CNS involvement at 
diagnosis or relapse (Okuno et al. 1995, Saito 1996, Stallone et al. 2000, Villa et al. 2011). 
Prognosis is poor, although long-term survivors have also been reported (Okuno et al. 1995, 
Saito 1996). For unilateral disease, extended disease-free intervals can occur following 
surgical resection, chemotherapy and consolidation radiation therapy (Okuno et al. 1995). 
CHOP protocols are recommended for bilateral disease (Navas Martinez et al. 2011, Villa et 
al. 2011). 
 
The purpose of this retrospective study was to gather information from dogs with presumed 
primary  renal  lymphoma,  characterising  the  clinical  presentation,  response  to 
chemotherapy and outcome, and to examine prognostic factors for this rare condition. 
 
 
 
Materials and Methods 
 
Inclusion/exclusion criteria 
 
Dogs were included if they had a cytologic or histologic diagnosis of lymphoma obtained 
from renal samples and tumour burden was largest in the kidney(s). The latter was 
determined by a board certified veterinary radiologist. Dogs diagnosed at necropsy that had 
not received cytotoxic treatment but fulfilled the above criteria were included. Cases with 
suspected or confirmed hepatic, splenic, peritoneal, abdominal or thoracic lymph node 
involvement were eligible for inclusion if the main clinical presentation was associated with 
renal infiltration (azotaemia with decreased urine concentration). Dogs with peripheral 
lymphadenomegaly, lymphoma in peripheral nodes (regardless of size) or a mediastinal 
mass at diagnosis were excluded. 
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Case selection and medical record review 
 
Cases  were  recruited  through  the  American  College  of  Veterinary  Internal  Medicine 
Oncology email listserv and by contacting other institutions in the UK. Medical records were 
retrospectively searched at seven veterinary teaching hospitals (Royal Veterinary College; 
University of Liverpool; The Ohio State University; Michigan State University; University of 
Cambridge; Washington State University; Hokkaido University) and four private veterinary 
referral centres (Veterinary Oncology Consultants; Veterinary Oncology & Hematology 
Center; Veterinary Specialty Care) from 2003 to 2017. Follow-up information was obtained 
from records and telephone conversation with referring veterinarians. 
 
Data recorded included signalment, presenting clinical signs and duration, physical exam 
findings, date of diagnosis and method, lymphoma grade and immunophenotype, diagnostic 
imaging and laboratory results. Clinicopathological results were classified as normal or 
abnormal by comparison with established reference ranges for the relevant laboratory.  If 
reference ranges were not listed, dogs were considered to have anaemia if the 
haematocrit was <37% and erythrocytosis if >55%. The International Renal Interest Society 
(IRIS) Classification Scheme for Acute Kidney Injury (AKI) was used to categorise dogs using 
serum creatinine concentration (and clinical parameters, if available): Grade I (≤1.6 mg/dl, 
<140 μmol/l; non-azotaemic with historical, imaging or laboratory evidence of AKI), Grade  II  
(1.7–2.5  mg/dl,  141–220 μmol/l; mild  AKI),  Grade  III  (2.6–5.0  mg/dl,  221–439 μmol/l; 
moderate to severe AKI), Grade IV (5.1–10.0 mg/dl, 440–880 μmol/l), and Grade V (>10.0 
mg/dl, >880 μmol/l; moderate to severe AKI) (Ettinger et al. 2017). Urine specific gravity 
(USG) 1.008 to 1.012 was considered isosthenuric and hyposthenuric when >1.008. A systolic 
blood pressure ≥160 mmHg was considered hypertensive. Protocols, responses, cause of 
death, and necropsy results were recorded when available. 
 
Dogs were classified using the World Health Organization (WHO) staging system and further 
characterised as substage a or b (Owen 1980). Because the kidney constitutes an extranodal 
form, dogs were also classified according to the Ann Arbor staging system in which stage I is 
defined as a single extranodal organ; II as for I but also including nodes on the same side of 
the diaphragm with or without spleen involvement (in the case of renal lymphoma); III 
including nodes on both sides of the diaphragm; and, IV defined by liver involvement or 
further dissemination (Carbone et al. 1971). Information regarding renal lesions and extent 
of disease was gathered from imaging reports (CT, thoracic radiography, abdominal 
ultrasonography or a combination thereof). Abnormalities that were not sampled were 
presumed to be involved in the disease process based on imaging reports and the opinion of 
the overseeing clinician. Bone marrow sampling was not routinely performed. 
 
Information on chemotherapy protocols was noted. For comparative purposes, induction 
protocols were classified as COP (an 8-week protocol utilising cyclophosphamide, vincristine 
and prednisolone with or without cytarabine on the first day of treatment) or CHOP (19- or 
25-week  protocols  consisting  of  cyclophosphamide,  vincristine,  prednisolone  and 
doxorubicin with or without L-asparaginase at induction; epirubicin was allowed as 
substitution for doxorubicin) (Withrow et al. 2013). A protocol was required to proceed for a 
minimum of 28 days to be classed as either COP or CHOP; dogs that died, were euthanised, 
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or whose treatment was changed before this, were excluded from statistical comparison of 
induction protocols. 
 
Response to treatment was determined by re-evaluation visit records and by the 
combination of the following when assessed a minimum of 10 days later: serum creatinine 
concentration, clinical signs, physical exam and renal lesions assessed by imaging. Complete 
response was defined as resolution of clinical signs, azotaemia, normal physical examination 
and/or no imaging abnormalities. Partial response was defined as a >50% but <100% 
improvement in one or more of the above variables. No response was defined as <50% 
improvement in one or more of the above variables (Taylor et al. 2009). 
 
Objective response rate was defined as the sum of complete and partial response rates. 
Dogs that died or were euthanised within 10 days of starting chemotherapy regardless of 
cause were not considered as responders. Progression-free survival was defined as the time 
from  initiating  chemotherapy  treatment  (a  cytotoxic  drug,  glucocorticoids  or  L- 
asparaginase) to disease relapse (after initial improvement), progression or death due to 
any cause. Overall survival was defined as the time from chemotherapy administration to 
death or euthanasia for any cause (Morrison-Collister et al. 2003). Dogs that remained alive 
and in remission at the end of the follow-up period or were lost to follow-up were censored 
from progression-free survival. Dogs that were alive or lost to follow-up at time of writing 
were censored from overall survival analysis. 
 
 
 
Statistical analysis 
 
The following clinical variables were evaluated: age, gender, weight, duration of clinical 
signs, polyuria/polydipsia, gastrointestinal signs, lethargy, inappetence, weight loss, CNS 
signs  (seizures,  cranial  or  spinal  cord  neuropathy),  fever, erythrocytosis, 
hyperphosphatemia, hypoalbuminemia, azotaemia, IRIS AKI grade, hypertension, 
renomegaly, pyelectasia, loss of corticomedullary distinction, unilateral/bilateral renal 
lesions, Ann Arbor stage, immunophenotype, lymphoma cell size, treatment protocol, 
addition  of  cytarabine  to  induction  protocol,  addition  of  L-asparaginase  to  induction 
protocol and response to chemotherapy. Data were described and analysed using SPSS 
version 24 (IBM Corp.). Descriptive parameters were evaluated for all data variables. 
Categorical data were presented either as percentages or ratios. Continuous data were 
expressed as median and range. Following statistical description, survival analysis using 
Kaplan-Meier product-limit method was conducted to estimate overall progression-free 
interval and overall survival for the dogs treated solely with chemotherapy. Data were 
assessed for normality by visual plotting and the Shapiro-Wilk test. Univariable and 
multivariate analysis were not performed due to the small data set. 
 
 
 
Results 
 
Signalment and clinical signs 
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Twenty-nine dogs fulfilled the inclusion criteria. Seven dogs had been included in a study 
evaluating ultrasonographic features of canine renal lymphoma (Taylor et al. 2014). A 
summary of the clinical and clinicopathologic data is listed in Table 1. The median age was 7 
years (range 3–14) and body weight 33 kg (range 9–53). Male to female ratio was 3.1:1. 
There were 10 Labrador Retrievers, six mixed-breed dogs, two Border Collies, and one each 
of  Doberman,  rottweiler,  Newfoundland,  Norwegian  elkhound,  Bernese  mountain  dog, 
West Highland terrier, Australian shepherd, Dalmatian, beagle, dogue de Bordeaux, and 
Shetland sheepdog. 
 
Clinical  presentation data were available for  all  dogs.  Median duration  of  clinical signs 
before presentation was 18 days (range: 2–210). Lethargy (n=2-; 69%), vomiting (n=24; 
48%), polyuria/polydipsia (n=12; 41%), decreased appetite (n=11; 38%), weight loss (n=6; 
21%), diarrhoea (n=6; 21%), and gross haematuria (n=4; 14%) were common. 
 
On physical examination, renomegaly was suspected in 16 (55%) dogs and 12 (41%) had 
pain on abdominal palpation. Neurologic signs (n=4; 14%) were comprised of Horner’s 
syndrome and trigeminal neuropathy (n=1; 3%), facial nerve paralysis (n=1; 3%), nystagmus 
(n=1; 3%), and upper motor neuron signs and hindlimb ataxia (n=1; 3%). Two dogs (7%) 
were pyrexic. Hypertension (range 160–230 mmHg) was present in 15 of 22 (68%) dogs. 
 
 
 
Clinicopathologic findings 
 
Haematological tests revealed mild anaemia (n=4, 14%; range 27–36%) and erythrocytosis 
(n=15, 51%; range 56–76%). Erythropoietin levels were measured in four cases and were 
normal in two and above reference interval in two. There were no reports of abnormal 
circulating lymphocytes on routine haematology or smear (when performed). No dogs had 
bone marrow sampling performed. 
 
Serum biochemical profile of all dogs revealed elevated creatinine concentration in 25 (86%; 
range 1.61–9.86 mg/dL), hyperphosphatemia in 14 (48%; range 4.9–11.6 mg/dL), 
hyperkalemia in 8 (28%; range 2.8–6.8 mEq/L), hypoalbuminemia in 5 (17%; range 2.1–2.7 
g/dL), and elevated alkaline phosphatase (ALP) and alanine aminotransferase activity (ALT) 
in 4 (14%) patients each (range 150–4549 IU/L and 84–885 IU/l, respectively). With the 
exception of one dog with an intrahepatic thrombus and markedly increased ALP and ALT, 
elevation of ALP and ALT were mild or moderate. None of the dogs was hypercalcemic. 
Based on IRIS AKI guidelines, four (14%) were Grade I; ten (34%) Grade II; nine (31%) Grade 
III; five (17%) Grade IV and one (3%) Grade V. 
 
Urine samples, acquired prior to fluid therapy when possible, were evaluated in all dogs. 
Findings included normal concentrating ability (n=1; 3%), USG >1.012 and <1.025 (n=15; 
52%), isosthenuria (n=11; 38%) and hyposthenuria (n=1; 3%). Urine sediment or dipstick 
analysis of 27 dogs revealed haematuria (n=18; 67%), proteinuria with inactive sediment 
(n=4; 15%), bacteriuria (n=4; 15%), pyuria and casts (n=3; 11% each), and atypical 
lymphocytes (n=1; 4%). Urine culture on four of 17 (24%) samples were positive for bacterial 
growth. 
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Diagnostic imaging findings 
 
Three-view thoracic radiographs performed in 25 dogs detected no abnormalities in 19 
(76%), and concurrent thoracic CT in one dog was normal. Abnormalities included sternal 
lymphadenopathy (n=3; 12%), mild pleural effusion (n=1; 4%), tracheobronchial 
lymphadenopathy (n=1; 4%) and a diffuse peribronchial and interstitial lung pattern and 
concurrent tracheobronchial lymphadenopathy (n=1; 4%). Bronchoalveolar lavage in the 
latter dog did not detect evidence of lymphoma. Cytology of an enlarged sternal lymph 
node in one dog confirmed lymphoma. 
 
Abdominal ultrasonography was performed in all dogs at presentation. Bilateral renal 
abnormalities were described in 23 (79%) and unilateral lesions in 6 (21%). Lesions included 
renomegaly (n=22; 76%), pyelectasia (n=21; 72%), loss of corticomedullary distinction (n=17; 
59%), subcapsular hypoechoic lesions (n=3; 10%) and diffuse hypoechogenicity (n=6; 21%) 
or hyperechogenicity (n=2; 7%). Mild renal abnormalities were described in two dogs with 
erythrocytosis and azotaemia, consisting of bilateral pyelectasia (n=2) and focal unilateral 
loss of corticomedullary distinction (n=1). Bilateral lymphoma was confirmed in both, one by 
cytology and biopsy and one at necropsy following deterioration a few days later in which a 
diffuse renal infiltration without renomegaly was found. 
 
Other lesions reported on abdominal ultrasonography included lymphadenopathy (n=14) 
including renal (n=4) and other nodes (mesenteric or sublumbar; n=8), both renal and other 
abdominal nodes (n=2), hepatic abnormalities (n=6) including one additional dog with an 
intrahepatic portal thrombus, and splenic abnormalities (n=4). Sampling of a solitary 1.7 cm 
diameter nodule revealed benign hyperplasia, and nodules in the other two dogs and one 
dog with hepatomegaly were consistent with lymphoma. Splenic cytology for two of three 
dogs were confirmed as lymphoma. Other ultrasonographic lesions included focal 
gastrointestinal wall abnormalities (n=4), adrenal enlargement or mass (n=3), peritoneal 
effusion (n=4), hyperechoic mesentery (n=2), thickened gall bladder wall (n=1), thickened 
and hypoechoic pancreas in which lymphoma was not found (n=1), and prostatomegaly 
(n=1). Fine needle aspiration of non-renal lesions confirmed neoplastic infiltration in four of 
nine liver, three of 11 spleen, one of one peritoneal effusion and eight of 10 abdominal 
lymph node samples. A cytologically reactive mesenteric node in one dog was confirmed as 
lymphoma by histopathology. 
 
Abdominal CT of one dog demonstrated heterogeneous contrast enhancement of the 
kidneys with suspected haemorrhage. A CT/excretory urogram in another dog revealed 
decreased unilateral contrast uptake and abnormal filling of the pelvis and ureter. No other 
lesions were reported. 
 
 
 
Diagnosis and disease staging 
 
A cytological diagnosis of lymphoma was obtained in 24 of 26 dogs that underwent fine- 
needle aspiration from the kidney, and in five dogs by biopsy and histopathology, includeing 
one diagnosed at necropsy 6 days after presentation. Immunotyping resulted in 6 of B-cell 
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and  10  T-cell  origin,  diagnosed  by  immunocytochemistry  (n=3),  immunohistochemistry 
(n=7),  flow  cytometry  (n=3),  and  PARR  (n=3)  designated  six  as  B-cell  and  10  as  T-cell 
tumours. All PARR results demonstrated clonal rearrangement. One additional case was an 
LGL variant. Neoplastic lymphoid morphology was described in 24/29 cases: large (n=12; T- 
cell n=5), intermediate-to-large (n=4; B-cell n=1), intermediate (n=3; T-cell n=2), small-to- 
intermediate (n=3; T-cell n=1) and small (n=2; T-cell n=1). 
 
Based on clinical exam findings and staging tests, all dogs were considered WHO stage Vb 
(Withrow et al. 2013). The Ann Arbor system classified six dogs as stage I, six stage II, three 
stage III and fourteen stage IV. 
 
 
 
Treatment and outcome 
 
Twenty-four dogs were treated; 23 received chemotherapy alone and one dog with a 
unilateral renal mass and mesenteric lymph node involvement underwent nephrectomy 
followed by a COP protocol. It was euthanised due to unknown causes at 2046 days, and 
was excluded from survival analyses because of its multimodal therapy. The five untreated 
dogs were euthanised at diagnosis (n=2) or 6, 8, and 15 days later. 
 
Of the 23 dogs treated only with chemotherapy, the intention-to-treat protocol was COP 
(n=12, including induction with cytarabine, n=7; or L-asparaginase, n= 4) and CHOP (n=8, 
including L-asparaginase at induction, n=4). The intended protocol was not clear for two 
dogs   that   received   L-asparaginase   and   prednisone,   and   one   dog   vincristine   and 
prednisolone.  Twelve  dogs  (52%)  were  excluded  in  response  evaluation  that  were 
euthanised  due  to  progressive  renal  disease  (n=7,  considered  non-responders)  or  died 
within 1 week of treatment (n=5) due to respiratory arrest, sepsis, biliary obstruction 
secondary to cholelithiasis, persistent seizures and unknown causes, respectively. 
 
Eleven dogs (48%) responded to chemotherapy, all with a partial response, treated with 
CHOP (n=5), COP (n=2) or a protocol that could not be defined because duration of therapy 
was <28 days (n=4). The median progression-free survival was 10 days (1–126) for all dogs 
treated with chemotherapy and 41 days (10–126) for responders. The median PFS for dogs 
treated with COP was 8 days (3–126) and 41 days (3–96) for CHOP. 
 
At follow up dogs were euthanased for suspected unrelated causes (n=2, sepsis and 
thromboembolism, respectively) and progressive disease (n=13). Nine of these died or were 
euthanased because of renal disease, and four because of CNS signs (presumed lymphoma- 
related). Various rescue treatments were used in four dogs but responses were short-lived 
with a median progression-free survival of 12 days (range 1–16). 
 
The median overall survival for dogs treated with chemotherapy was 12 days (range 1–212) 
with 30% alive one month after treatment initiation and only one alive at 6 months. The 
median overall survival for dogs that responded to chemotherapy was 47 days (range 10– 
212). Outcome data are listed in Table 2, and the corresponding survival curve is show in Fig. 
1. 
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Four dogs underwent necropsy of which the diagnosis was achieved at that time in one. 
Findings included cream-coloured masses that replaced or compressed renal parenchyma 
and focal haemorrhages (Fig. 2). Microscopically there were neoplastic cells, suppurative 
inflammation and necrosis, with compression and occasional fibrosis of tubules (Fig. 3). Of 
the chemotherapy-treated dogs, one had no extra-renal lesions at necropsy three days after 
receiving chemotherapy, and the other had renal lymphadenopathy and hepatic nodules 
found by ultrasound but additional lesions (adrenal, mediastinal and mesenteric node) at 
necropsy 4 days after starting chemotherapy. Of the two untreated dogs, no extra-renal 
lesions were found on ultrasound or necropsy in one, and ultrasound of the other revealed 
only renal lesions and a hypoechoic pancreas but involvement of pituitary, adrenal, spleen 
and liver at necropsy a few days later. None of these dogs had liver or spleen sampled. 
Thoracic imaging findings were reported as unremarkable in all four, including the dog 
diagnosed with a mediastinal mass at necropsy that underwent CT. All four exhibited 
neurological signs before death but CNS involvement was confirmed in only one dog. 
 
 
 
Discussion 
 
Our data demonstrate the poor prognosis of dogs with presumed primary renal lymphoma, 
even with initiation of a multiagent chemotherapy protocol. Despite many (48%) responding 
to treatment, the median progression-free survival for these was 41 days and none had a 
complete response. The median overall survival, 47 days, was short. 
 
The reason for these grave outcomes are likely multifactorial. Dogs with an extranodal 
abdominal form typically present with non-specific signs and diagnosis is more likely at an 
advanced stage (Couto et al. 1989, Dank et al. 2011). All dogs were systemically ill at 
diagnosis and in poor condition, and substage is a known prognostic factor for canine 
lymphoma (Keller et al. 1993). Similarly, the response duration for responders was short and 
the overall response rate to chemotherapy was substantially low compared to canine 
peripheral nodal lymphoma (Simon et al. 2008). Moreover, there were no complete 
responses. Finally, T-cell phenotype appeared to predominate, which may have contributed 
to the poor chemotherapy response observed; intrinsic drug resistance is common with this 
form and is associated with increased ABCG2 expression (Zandvliet et al. 2015). 
 
The study was limited by variable re-evaluation intervals and methods. In addition, we 
chose to use 10 days as a minimum duration of response rather than 42 days as for 
peripheral nodal lymphoma (Vail et al. 2010) because many dogs in our study were found to 
respond to chemotherapy despite short survival times. In an effort to avoid understating 
treatment response in this aggressive form, a shorter duration was evaluated instead, 
because some dogs had reasonable outcomes. 
 
Most dogs in this study were azotaemic at presentation. However, the AKI grading system, 
as determined by a single measurement, reflects a moment in the disease course. In 
addition, the mechanism of renal failure in human primary renal lymphoma is thought to be 
neoplastic infiltration and compression of the tubular lumen resulting in intrarenal 
obstruction, leading to tubular atrophy and necrosis (Glicklich et al. 1986). The canine 
necropsies demonstrated these lesions microscopically. As such, the degree of azotaemia 
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may not be truly reflective of the damage done to the kidneys. Finally, interpretation bias in 
the face of severe azotaemia may result in reluctance to treat. 
 
In this study, clinical signs, physical exam, imaging and biochemical findings were used to 
determine  response,  as  standardised  response  evaluation  criteria  are  not  available  for 
canine extra-nodal lymphoma. While data reassessing renal values were not available for all, 
5/11 dogs had improved or resolved azotaemia. Similarly, improvement in serum creatinine 
values is associated with longer survival in human primary renal lymphoma (Glicklich et al. 
1986). In addition, one dog demonstrated improved clinical signs while ultrasound 
abnormalities remained unchanged. Sonographic lesions in human primary renal lymphoma 
may persist despite resolution of symptoms and histopathologic absence of disease (Choi et 
al. 1997). 
 
The longest survivor was a dog with unilateral disease and mesenteric lymph node 
involvement that lived over five years following nephrectomy and a COAP protocol. The 
prognosis for human primary renal lymphoma is guarded with conventional chemotherapy 
alone. However, in unilateral cases with no extra-renal involvement, nephrectomy followed 
by chemotherapy is recommended, with long-term survivors reported (Okuno et al. 1995). 
This suggests that dogs with unilateral disease and no extra-renal involvement may benefit 
from nephrectomy. 
 
Thirteen dogs exhibited neurologic signs either at diagnosis or disease progression. Renal 
involvement of lymphoma is an independent risk factor for CNS relapse in people, possibly 
due to chemokines, adhesion molecules, and matrix metalloproteinases aiding invasion into 
the nervous system (Villa et al. 2011). Necropsy of only one of four dogs revealed infiltration 
in the CNS. Five presented with concurrent neurologic signs and erythrocytosis (range 56– 
73%); erythropoietin levels were normal when measured (n=2). While it is possible that 
dehydration caused a relative polycythemia, total protein was elevated in only one dog; 
after fluid therapy, the total protein normalized but erythrocytosis persisted. Blood 
hyperviscosity can lead to complications such as neurologic signs, cardiac or renal function 
compromise, weakness, or thromboembolic disease (Ettinger et al. 2017). Erythrocytosis, 
common in this study and comprising seven T-cell, one B-cell, and one LGL type, has been 
associated with various canine renal neoplasms (Bennett 2004, Cook & Lothrop 1994) in 
addition to renal lymphoma. Finally, hypertensive encephalopathy can initiate CNS signs 
through rapid rise in pressure altering cerebrovascular flow (Becker et al. 2007, Ettinger et 
al. 2017). Although blood pressure measurements can be falsely elevated in the veterinary 
hospitals, 9/11 dogs with neurological signs were diagnosed as hypertensive. 
 
Ultrasonography demonstrated renal abnormalities in all dogs. In two, subtle findings were 
nonspecific and not considered clinically meaningful at the time. Further investigations 
revealed azotaemia and erythrocytosis in both and lymphoma was diagnosed either at 
necropsy or when marked imaging abnormalities later prompted sampling. Preservation of 
renal shape and size is documented in human primary renal lymphoma, indicating an 
infiltrative rather than expansile growth pattern in some cases (Hartman et al. 1988). This 
suggests  that   if   erythrocytosis  or   azotaemia  is   diagnosed  but   imaging  lesions   are 
nonspecific, an infiltrative process such as lymphoma should be a differential diagnosis and 
renal sampling may be indicated. 
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There are several limitations of the data presented in the current study. First, the low 
number of cases – because of the rarity of this disease – limits statistical power to detect 
prognostic markers. Because dogs with predominant disease in non-renal locations were 
excluded, those with initial renal localisation and subsequent rapid dissemination may have 
been omitted (Krol et al. 2003). Conversely, those with disease originating elsewhere and 
then disseminating to the kidneys may have been erroneously included; in this study only six 
dogs had disease limited to the kidney according to available staging data, though one did 
not have thoracic imaging and not all had both spleen and liver sampled. However, those 
with Stage I disease did not have improved or worse outcomes compared to dogs of higher 
Ann Arbor stage. 
 
Clear guidelines to classify primary renal lymphom versus secondary renal lymphoma are 
lacking  in  both  human  and  veterinary  medicine,  but  recommendations  for  staging  in 
humans include advanced thoracoabdominal imaging and bone marrow biopsy (Cheson et 
al. 2014). Primary renal lymphoma cases with disseminated disease have been reported 
using a broader definition of primary extra-nodal lymphoma that consideres extent of 
disease (Geetha et al. 2014, Jipp et al. 2016), although this risks erroneously including cases 
that have originated elsewhere and subsequently disseminate to the kidney. Evaluation of 
the impact of alternative definitions for human extra-nodal lymphoma revealed similar 
patient outcomes regardless of categorisation and, as a result it is advocated to include 
those with disseminated disease at presentation provided the extranodal component is 
clinically predominant (Krol et al. 2003). This criterion reduces selection bias for lower-stage 
disease. In the veterinary medicine, classification of primary forms of lymphoma have been 
less restrictive, allowing inclusion of cases with concurrent abdominal lymph node, splenic, 
or hepatic involvement (Dank et al. 2011, Desmas et al. 2017), and cats with other organ 
involvement have been included in large studies describing feline renal lymphoma (Mooney 
et al. 1987, Taylor et al. 2009). As such, the use of more liberal criteria for certain cases of 
primary extra-nodal lymphoma (Krol et al. 2003) seems reasonable because the outcome 
does not appear affected. 
 
As seen with two dogs in this study, cases may go undiagnosed if subtle renal lesions do not 
prompt sampling. In addition, systematic sampling of bone marrow, both kidneys or non- 
renal lesions was not always performed, and so bilateral disease or other organ involvement 
may have been underrepresented, and four dogs lacked thoracic imaging. This may have 
resulted in Ann Arbor stage migration. Histology and cytology slides did not undergo second 
review and immunophenotyping and cell morphology data were not available for all. Three 
dogs were diagnosed as B- or T-cell by PARR; detection of clonal antigen receptor 
rearrangement can also occur with infectious diseases (Burnett et al. 2003) though these 
are rare where the dogs resided (UK and Japan). As with other veterinary studies, survival 
times may be affected by decisions of owners to euthanise rather than reflecting the true 
nature of the disease. Finally, cases were managed by different clinicians with varied 
chemotherapeutic protocols and heterogeneous assessment of response, precluding 
evaluation of the efficacy of particular drugs/protocols. 
 
Presumed primary renal lymphoma in dogs is associated with high morbidity, a short-lived 
response to multi-agent chemotherapy and poor prognosis. Further studies are needed to 
11  
identify effective therapy and prognostic factors and to assess the role of surgery and 
adjuvant chemotherapy in the treatment of unilateral Stage I disease. 
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Table 1. Clinical and clincopathologic data for dogs with presumed primary renal lymphoma 
 
Characteristics Number affected (range) 
Clinical characteristics 
Age (year) 7 (3–14) 
Sex 
Neutered male 14 
Intact male 8 
Neutered female 5 
Intact female 2 
Weight (kg) 33 (9–53) 
Clinicopathologic characteristics 
Hypertension 
Yes 15 
No 7 
Erythrocytosis 
Yes 15 
No 14 
Elevated creatinine 
Yes 25 
No 4 
Urine concentration 
Moderate to maximal (≥ 1.025) 1 
Minimal (> 1.012 but < 1.025) 15 
Isosthenuric 11 
Hyposthenuric 1 
Ultrasonographic renal lesions 
Bilateral 23 
Unilateral 6 
Immunophenotype 
B-cell 6 
T-cell 10 
Ann Arbor stage 
I 6 
II 6 
III 7 
IV 10 
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Table 2. Outcome of 23 dogs with presumed primary renal lymphoma treated with 
chemotherapy alone 
 
Variable (n) Median PFS (range) Median OS (range) 
All 10 days (1–126) 12 days (1–212) 
 
COP (12) 
 
8 days (3–126) 
 
22 days (4–212) HOP (8) 41 days (3–9 37 3 104
L-asparaginase/prednisone (2)  (3–29) days 
Vincristine/prednisolone (1)  3 days 
 
Treated with rescue (4) 
 
12 days (1–16) 
 
54 days (21–212) Responded to treatment (11) 4  days (10 26) 47 10
 
 
 
 
 
Fig 1. Kaplan Meier survival curves for dogs with presumed primary renal lymphoma treated 
with chemotherapy. The dotted line represents dogs that responded to chemotherapy, and 
the black line represents dogs that did not respond. 
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Figure 2. Haemorrhage and clotted blood extending multifocally from the capsule to the 
pelvis in a dog with presumed primary renal lymphoma. 
 
 
 
 
 
 
Figure 3. Marked expansion of the cortical interstitium by sheets of neoplastic lymphocytes, 
compressing  and  effacing  tubules  and  surrounding  glomeruli  in  a  dog  with  presumed 
primary renal lymphoma (hematoxylin and eosin stain, bar=50 μm). 
 
 
